GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESAIY) » Definitions » Cyclically Adjusted Revenue per Share

Eisai Co (Eisai Co) Cyclically Adjusted Revenue per Share : $12.22 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Eisai Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Eisai Co's adjusted revenue per share for the three months ended in Mar. 2024 was $1.108. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $12.22 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Eisai Co's average Cyclically Adjusted Revenue Growth Rate was -3.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Eisai Co was -0.70% per year. The lowest was -3.00% per year. And the median was -1.90% per year.

As of today (2024-05-22), Eisai Co's current stock price is $10.475. Eisai Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $12.22. Eisai Co's Cyclically Adjusted PS Ratio of today is 0.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eisai Co was 1.54. The lowest was 0.64. And the median was 0.91.


Eisai Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Eisai Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Cyclically Adjusted Revenue per Share Chart

Eisai Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.59 70.95 61.93 14.48 12.22

Eisai Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.48 13.17 12.75 13.23 12.22

Competitive Comparison of Eisai Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eisai Co's Cyclically Adjusted PS Ratio falls into.



Eisai Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eisai Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.108/107.2000*107.2000
=1.108

Current CPI (Mar. 2024) = 107.2000.

Eisai Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.556 98.000 4.984
201409 4.426 98.500 4.817
201412 4.079 97.900 4.466
201503 4.059 97.900 4.445
201506 3.930 98.400 4.281
201509 3.960 98.500 4.310
201512 4.332 98.100 4.734
201603 3.753 97.900 4.110
201606 4.543 98.100 4.964
201609 4.560 98.000 4.988
201612 4.193 98.400 4.568
201703 4.015 98.100 4.387
201706 4.465 98.500 4.859
201709 4.513 98.800 4.897
201712 4.783 99.400 5.158
201803 5.280 99.200 5.706
201806 4.859 99.200 5.251
201809 4.881 99.900 5.238
201812 4.885 99.700 5.252
201903 5.505 99.700 5.919
201906 4.971 99.800 5.340
201909 4.713 100.100 5.047
201912 5.973 100.500 6.371
202003 6.782 100.300 7.249
202006 5.368 99.900 5.760
202009 5.003 99.900 5.369
202012 6.092 99.300 6.577
202103 4.736 99.900 5.082
202106 1.575 99.500 1.697
202109 5.175 100.100 5.542
202112 1.555 100.100 1.665
202203 1.404 101.100 1.489
202206 1.199 101.800 1.263
202209 1.061 103.100 1.103
202212 1.212 104.100 1.248
202303 1.293 104.400 1.328
202306 1.215 105.200 1.238
202309 1.041 106.200 1.051
202312 1.076 106.800 1.080
202403 1.108 107.200 1.108

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Eisai Co  (OTCPK:ESAIY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eisai Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.475/12.22
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eisai Co was 1.54. The lowest was 0.64. And the median was 0.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Eisai Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Eisai Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (Eisai Co) Business Description

Industry
Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.